

- 5-TR. Praktická příručka s kódy MKN-10 a MKN-11. Hogrefe – Test centrum s.r.o., Praha, 2023
8. 10. revize Mezinárodní klasifikace nemocí, česká verze, platnost od 1. 1. 2023. <https://mkn10.uzis.cz/prohlizec/F10-F19>
  9. Perälä J, Kuoppasalmi K, Pirkola S, et al. Alcohol-induced psychotic disorder and delirium in the general population. *J Psychiatry*. 2010 Sep;197(3):200-6.
  10. Jordaán GP, Nel DG, Hewlett RH, et al. Alcohol-induced psychotic disorder: a comparative study on the clinical characteristics of patients with alcohol dependence and schizophrenia. *J Stud Alcohol Drugs*. 2009 Nov;70(6):870-6.
  11. Soyka M. Psychopathological characteristics in alcohol hallucinosis and paranoid schizophrenia. *Acta Psychiatr Scand*. 1990 Mar;81(3):255-9.
  12. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. *Eur Arch Psychiatry Clin Neurosci*. 2009 Oct;259(7):413-31.
  13. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 2007;370(9584):319-28.
  14. Schoeler T, Ferris J, Winstock AR. Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis. *Transl Psychiatry*. 2022 Sep 6;12(1):369.
  15. Padhi D, Shukla P, Chaudhury S. Sociodemographic and clinical profile of cannabis-induced psychosis: A comparative study. *Ind Psychiatry J*. 2021 Oct;30(Suppl 1):S132-S139.
  16. Núñez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. *Acta Psychiatr Scand*. 2002 Mar;105(3):173-8.
  17. Vergara-Moragues E, Mestre-Pintó JI, Gómez PA, et al. Can symptoms help in differential diagnosis between substance-induced vs independent psychosis in adults with a lifetime diagnosis of cocaine use disorder? *Psychiatry Res*. 2016 Aug 30;242:94-100.
  18. Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. *J Anal Toxicol*. 1999;23:323-332.
  19. Vergara-Moragues E, González-Saiz F, Lozano OM, et al. Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. *Psychiatry Res*. 2012 Dec 30;200(2-3):734-41.
  20. Roncero C, Comín M, Daigre C, et al. Clinical differences between cocaine-induced psychotic disorder and psychotic symptoms in cocaine-dependent patients. *Psychiatry Res*. 2014 May 30;216(3):398-403.
  21. Fiorentini A, Cantù F, Crisanti C, et al. Substance-Induced Psychoses: An Updated Literature Review. *Front Psychiatry*. 2021 Dec 23;12:694863.
  22. Arunogiri S, Verdejo-García A, McKetin R, et al. Emotion Recognition and Impulsive Choice in Relation to Methamphetamine Use and Psychosis Symptoms. *Front Psychiatry*. 2019 Dec 13;10:889.
  23. Hides L, Dawe S, McKetin R, et al. Primary and substance-induced psychotic disorders in methamphetamine users. *Psychiatry Res*. 2015 Mar 30;226(1):91-6.
  24. Gan H, Zhao Y, Jiang H, et al. A Research of Methamphetamine Induced Psychosis in 1,430 Individuals With Methamphetamine Use Disorder: Clinical Features and Possible Risk Factors. *Front Psychiatry*. 2018 Nov 6;9:551.
  25. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. *Am J Addict*. 2000 Winter;9(1):28-37.
  26. Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. *Int J Neuropsychopharmacol*. 2003 Dec;6(4):347-52.
  27. McKetin R, Baker AL, Dawe S, et al. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. *Psychiatry Res*. 2017 May;251:349-354.
  28. Voce A, Calabria B, Burns R, et al. A Systematic Review of the Symptom Profile and Course of Methamphetamine-Associated Psychosis. *Subst Use Misuse*. 2019;54(4):549-559.
  29. Sara G, Burgess P, Malhi GS, et al. Differences in associations between cannabis and stimulant disorders in first admission psychosis. *Schizophr Res*. 2013;147(2-3):216-22.
  30. Yui K, Goto K, Ikemoto S, et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. *Mol Psychiatry*. 1999 Nov;4(6):512-23.
  31. Wearne TA, Cornish JL. A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology. *Front Psychiatry*. 2018 Oct 10;9:491.
  32. Kopeček M, Andrashko V. Racemický ketamin v léčbě rezistentní depresivní poruchy. Od výzkumu ke klinické off-label aplikaci. *Psychiatrie*. 2022; 26(4): 146-155.
  33. Kopeček M, Andrashko V. Pokračovací a udržovací léčba rezistentní depresivní poruchy racemickým ketaminem. Přehled studií. *Psychiatrie*. 2023; 27(4): 168-178.
  34. Pereiro C, Pino C, Flórez G, Arrojo M, Becoña E; COPSIAD Group. Psychiatric Comorbidity in Patients from the Addictive Disorders Assistance Units of Galicia: The COPSIAD Study. *PLoS One*. 2013 Jun 18;8(6):e66451.
  35. Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. *Psychiatry Res*. 2011;186(2-3):356-361.
  36. Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. *Metab. Brain. Dis*. 2014; 29(2): 351-357.
  37. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. *Biol Psychiatry*. 2001 Jul 15;50(2):71-83.
  38. Green AI, Drake RE, Brunette MF, et al. Schizophrenia and co-occurring substance use disorder. *Am J Psychiatry*. 2007;164(3):402-8.
  39. Gicas KM, Parmar PK, Fabiano GF, Mashhadi F. Substance-induced psychosis and cognitive functioning: A systematic review. *Psychiatry Res*. 2022;308:114361.
  40. Caton CL, Hasin DS, Shrout PE, et al. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. *Br J Psychiatry*. 2007;190:105-11.
  41. Kittirattanaapaiboon P, Mahatnirunkul S, Booncharoen H, et al. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. *Drug Alcohol Rev*. 2010;29(4):456-61.
  42. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. *Am J Psychiatry*. 2018 Apr 1;175(4):343-350. doi: 10.1176/appi.ajp.2017.17020223. Epub 2017 Nov 28. Erratum in: *Am J Psychiatry*. 2019 Apr 1;176(4):324.
  43. Murrrie B, Lappin J, Large M, Sara G. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. *Schizophr Bull*. 2020 Apr 10;46(3):505-516.
  44. Niemi-Pynttari JA, Sund R, Putkonen H, et al. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. *J Clin Psychiatry*. 2013 Jan;74(1):e94-9.
  45. Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. *Br J Psychiatry*. 2005;187:510-5.
  46. Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. *Am J Psychiatry*. 2019;176(9):711-719.
  47. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. *Am J Psychiatr (Suppl.)* 1997; 154: 1-63.
  48. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. *Arch Gen Psychiatry*. 2005 Mar;62(3):247-53.
  49. Pompili M, Amador FX, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. *Ann Clin Psychiatry*. 2007; 6: 10.
  50. Chai Y, Luo H, Wei Y, et al. Risk of self-harm or suicide associated with specific drug use disorders, 2004-2016: a population-based cohort study. *Addiction*. 2022;117(7):1940-1949.
  51. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. *CNS Drugs*. 2014;28(12):1115-26.
  52. Masopust J, Kopeček M., Protopopová D. Stabilizační a udržovací léčba schizofrenie. Doporučené postup psychiatrické péče 2022. <https://postupy-pece.psychiatrie.cz/specialni-psychiatrie/f2-schizofrenie/stabilizacni-udrzovaci-lecba-schizofrenie>.
  53. Zarrabi H, Khalkhali M, Hamidi A, et al. Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients. *BMC Psychiatry*. 2016 Feb;16:44.
  54. Campbell EC, Caroff SN, Mann SC. Pharmacotherapy for co-occurring schizophrenia and substance use disorder. *UpToDate*. Waltham, MA, Wolters Kluwer Health. 2024 Feb.
  55. Medhus S, Mordal J, Holm B, et al. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. *Psychiatry Res*. 2013 Mar 30;206(1):17-21.
  56. Srisurapanont M, Arunpongpaal S, Wada K, et al. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011 Jun 1;35(4):959-64.
  57. Shelly J, Uhlmann A, Sinclair H, et al. First-Rank Symptoms in Methamphetamine Psychosis and Schizophrenia. *Psychopathology*. 2016;49(6):429-435.
  58. Wang LJ, Lin SK, Chen YC, et al. Differences in Clinical Features of Methamphetamine Users with Persistent Psychosis and Patients with Schizophrenia. *Psychopathology*. 2016;49(2):108-15.
  59. Sekiguchi Y, Okada T, Okumura Y. Treatment Response Distinguishes Persistent Type of Methamphetamine Psychosis From Schizophrenia Spectrum Disorder Among Inmates at Japanese Medical Prison. *Front Psychiatry*. 2021 Jul 19;12:629315.
  60. Hajebi A, Amini H, Kashani L, Sharifi V. Twelve-month course and outcome of methamphetamine-induced psychosis compared with first episode primary psychotic disorders. *Early Interv Psychiatry*. 2018 Oct;12(5):928-934.
  61. Jordaán GP, Emsley R. Alcohol-induced psychotic disorder: a review. *Metab Brain Dis*. 2014 Jun;29(2):231-43.
  62. Rentero D, Arias F, Sánchez-Romero S, et al. Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use. *Adicciones*. 2021 Mar 31;33(2):95-108.
  63. Rubio G, Marín-Lozano J, Ferré F, et al. Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis. *Compr Psychiatry*. 2012 Nov;53(8):1063-70.